RESUMEN
PURPOSE: This study undertook a systematic examination of YouTube videos about chemotherapy for pediatric patients, with a primary focus on assessing the videos' quality, content, and reliability. METHOD: The research was conducted by searching YouTube using the keywords "chemotherapy for children" and "chemotherapy for pediatric," employing filters for "worldwide" and "all categories." The top 100 videos, based on popularity, were selected for evaluation according to the power analysis calculation. Two independent experts in pediatric oncology reviewed these videos. Video characteristics were recorded: length, view count, likes, dislikes, view ratio, and video-like ratio. The Video Power Index was calculated to measure video popularity. The modified DISCERN and Global Quality Scale (GQS) assessed the videos for quality and reliability. RESULTS: The 100 videos were analyzed. Official health institutions uploaded 54%, while independent users contributed 46%. Independent user uploads garnered significantly more views than official health institutions (p = .006). The number of likes, view ratio, and Video Power Index of independent users' videos were significantly higher than official health institutions' videos (respectively, p = .007, .007, and .008). On the other hand, the modified DISCERN score and GQS were significantly higher in YouTube videos of official health institutions than in independent users (p < .001). A strong correlation was observed between the modified DISCERN score and GQS (r = .879, p < .001). CONCLUSION: This study provides valuable insights into the YouTube videos on pediatric chemotherapy, emphasizing the need to improve the quality and reliability of online health information for this vulnerable population.
Asunto(s)
Medios de Comunicación Sociales , Humanos , Niño , Reproducibilidad de los Resultados , Emociones , Oncología Médica , Extremidad SuperiorRESUMEN
OBJECTIVES: Colchicine intoxication is rare but potentially fatal. The toxic dose of colchicine is not well established; it has been reported that major toxicity starts after doses of 0.5 mg/kg. We aimed to evaluate the demographic, clinical aspects, treatments, and outcome of colchicine toxicity cases in the pediatric intensive care unit (PICU). METHODS: We collected the data of patients aged between 0 and 18 years, admitted to Ankara University Faculty of Medicine PICU for colchicine poisoning (n = 22), from October 1999 to January 2020, retrospectively. Data extracted from the cases included age, sex, chronic condition, time between intake of drug and admission to PICU, source of drug, amount of drug ingested, other drug intake, symptoms, clinical findings, cardiac involvement, laboratory results, time of stay in PICU, treatment, and outcome. RESULTS: Patients' age ranged from 7 months to 17 years. Median age was 86 months. The most common symptom at time of admission was vomiting, occurring in 13 (59%) of the patients. Two of the patients presented with change in mental status. Time between taking medication and applying to the hospital ranged from half an hour to 4 days. Medication intake of 3 of 22 patients was more than 0.5 mg/kg. One patient whose parents' best estimate of dose ingested was 0.48 mg/kg died because of the development of multiorgan failure. One patient who ingested 0.4 mg/kg of colchicine underwent plasma exchange and recovered without any complications. CONCLUSIONS: Colchicine poisoning has a high risk of mortality, and death can be seen in doses less than a single acute dose of 0.5 mg/kg. These patients need close monitoring because there is always a risk of them to require aggressive support. Prognosis is poor in patients who have rapidly developing hemodynamic failure.
Asunto(s)
Unidades de Cuidado Intensivo Pediátrico , Intoxicación , Adolescente , Niño , Preescolar , Colchicina , Humanos , Lactante , Recién Nacido , Intoxicación/epidemiología , Intoxicación/terapia , Pronóstico , Estudios Retrospectivos , VómitosRESUMEN
Objective: The use of virtual reality (VR) as a non-pharmacologic method may enable children to tolerate invasive procedures in a hospital setting easily and feel less pain. This study aimed at determining the effect of using a VR headset during venipuncture on pain level, heart rate (HR), and oxygen saturation values in children aged 7-12 years old. Materials and Methods: This was a randomized controlled experimental study. This study included 102 children (experimental group: 52; control group: 50) who visited a pediatric outpatient clinic of a university hospital in Turkey between May 2018 and May 2019. Data were collected using the Child and Family Information Form, State Anxiety Inventory for Children, Faces Pain Scale-Revised (FPS-R). Before venipuncture, state anxiety and pain scores of the children were evaluated. The children in the experimental group wore VR headsets during venipuncture. The children in the control group underwent standard venipuncture procedure. Pain scores were evaluated again in both groups after the venipuncture. Before, during, and after the venipuncture, pulse and oxygen saturation values were measured. Results: It was determined that post-procedure pain score was 1.46 ± 1.49 in the experimental group and 4.44 ± 2.26 in the control group. Post-venipuncture pain mean scores were significantly lower in the experimental group than those of the children in the control group (Z = -6.574; P = 0.001). Secondary outcomes: The mean HR during the procedure was significantly lower in the experimental group (99.27 ± 18.34/min) than in the control group (108.20 ± 21.42/min) (P = 0.026; t = -2.265). There was no statistically significant difference between the before and after the procedure difference of oxygen saturation values (Experimental group: -0.15 ± 1.54; Control Group: 0.04 ± 0.93) between groups (Z = -0.023; P = 0.982). Conclusion: It was determined that post-venipuncture pain mean scores were significantly lower in the experimental group than in the control group. VR is effective to reduce the pain of children during venipuncture. VR headsets may be recognized as effective instruments to reduce the pain level of children in hospital settings. (Clinicaltrials.gov: NCT04950478).